GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vicore Pharma Holding AB (STU:6Y4) » Definitions » Additional Paid-In Capital

Vicore Pharma Holding AB (STU:6Y4) Additional Paid-In Capital : €0.00 Mil(As of Mar. 2025)


View and export this data going back to 2020. Start your Free Trial

What is Vicore Pharma Holding AB Additional Paid-In Capital?


Vicore Pharma Holding AB's quarterly additional paid-in capital increased from Sep. 2024 (€0.00 Mil) to Dec. 2024 (€213.39 Mil) but then stayed the same from Dec. 2024 (€213.39 Mil) to Mar. 2025 (€0.00 Mil).

Vicore Pharma Holding AB's annual additional paid-in capital increased from Dec. 2022 (€110.14 Mil) to Dec. 2023 (€149.63 Mil) and increased from Dec. 2023 (€149.63 Mil) to Dec. 2024 (€213.39 Mil).


Vicore Pharma Holding AB Additional Paid-In Capital Historical Data

The historical data trend for Vicore Pharma Holding AB's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vicore Pharma Holding AB Additional Paid-In Capital Chart

Vicore Pharma Holding AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Additional Paid-In Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 69.00 99.47 110.14 149.63 213.39

Vicore Pharma Holding AB Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 213.39 -

Vicore Pharma Holding AB Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Vicore Pharma Holding AB Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Vicore Pharma Holding AB's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


Vicore Pharma Holding AB Business Description

Traded in Other Exchanges
Address
Kornhamnstorg 53, Stockholm, SWE, 111 27
Vicore Pharma Holding AB is a clinical-stage pharmaceutical company focused on severe lung diseases. The company is establishing a portfolio in respiratory diseases, including idiopathic pulmonary fibrosis (IPF). Its C21 is a small molecule angiotensin II type 2 receptor agonist (ATRAG) currently in phase 2b development for IPF. The company also has an investigational medical device in clinical development, namely, Almee, which is a digital therapeutic leveraging cognitive behavioral therapy created to address the psychological impact of living with pulmonary fibrosis.

Vicore Pharma Holding AB Headlines

No Headlines